Target to $16 from $8
Tuesday, July 23, 2019
Sanofi signs U.S. rights deal for Tamiflu
Sanofi (NASDAQ:SNY) has signed an exclusive rights deal with Roche (OTCQX:RHHBY) for ‘Tamiflu’ in the U.S., which is used for the prevention and treatment of flu.
“This is a strategic and important transaction for us as we strive to continually bring innovations to the market,” said Alan Main, executive vice president of Sanofi’s consumer healthcare division.
Medidata Solutions EPS beats by $0.09, beats on revenue
Medidata Solutions (NASDAQ:MDSO): Q2 Non-GAAP EPS of $0.48 beats by $0.09; GAAP EPS of $0.13 beats by $0.02.
Revenue of $180.46M (+15.7% Y/Y) beats by $0.51M.
Centene Q2 top line up 29%; earnings up 65%
Centene (NYSE:CNC) Q2 results ($M): Revenues: 18,356 (+29.4%); Premium: 16,554 (+36.7%).
Net income: 495 (+65.0%); non-GAAP net income: 561 (+55.8%); EPS: 1.18 (+57.3%); non-GAAP EPS: 1.34 (+48.9%).
Cash flow ops (6 mo.): 2,233 (+69.2%).
Health benefits ratio: 86.7%.
2019 guidance: Revenues: $73.6B – 74.2B from $72.8B – 73.6B; EPS: $3.70 – 3.87 from $3.67 – 3.84; non-GAAP EPS: $4.29 – 4.49 from $4.24 – 4.44.
Shares are down 1% premarket.
Previously: Centene EPS beats by $0.10, beats on revenue (July 23)
Quest Diagnostics Q2 revenues up 2%; earnings down 6%
Quest Diagnostics (NYSE:DGX) Q2 results ($M): Revenues: 1,953 (+1.8%).
Net income: 206 (-5.9%); non-GAAP net income: 237 (-3.3%); EPS: 1.51 (-3.8%); non-GAAP EPS: 1.73 (-1.1%).
Cash flow ops: 321 (-0.6%).
2019 guidance: Revenues: $7.60B – 7.75B (unch); EPS: >$5.29 from >$5.16; non-GAAP EPS: >$6.40 (unch); cash flow ops: ~$1.3B (unch).
Previously: Quest Diagnostics EPS beats by $0.05, beats on revenue (July 23)
Health Catalyst boosts size of IPO
Health Catalyst (HCAT) has filed another preliminary prospectus for an IPO of 7M common shares at $24 – 25 per share. On July 12, it filed for an offering of 6.9M shares at $20 – 23.
Subscribe to:
Comments (Atom)